Entrectinib medical insurance reimbursement conditions

Entrectinib (Entrectinib) is a drug used to treat specific types of cancer and is a type of targeted therapy drug. It is designed to fight cancers caused by specific genetic mutations, and has shown potential efficacy in the treatment of neuroblastoma (Neuroblastoma), non-small cell lung cancer (Non-Small Cell Lung Cancer, NSCLC) and other solid tumor types.

Reimbursement is limited only to: 1.12 years of age and older, solid tumors diagnosed with neurotrophic tyrosine receptor kinase (NTRK) fusion genes by well-validated testing methods and excluding known acquired drug resistance mutations: patients with locally advanced, metastatic disease Patients whose disease or surgical resection may lead to serious complications, or patients who have no satisfactory alternative treatment or whose previous treatment has failed; 2. Adult patients with ROS1positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Entrectinib is now available in China and included in the medical insurance system, and patients can purchase it domestically. However, it is quite expensive, costing about 20,000 yuan. For specific price information and medical insurance reimbursement details, patients are advised to consult their local hospital pharmacy for accurate information. In comparison, the price of foreign generic entrectinib drugs is relatively affordable, especially the generic drugs produced in Laos, which only cost about one to two thousand yuan. It is worth mentioning that the ingredients of these generic drugs are basically the same as those of the original drugs. Therefore, patients can choose a suitable treatment plan based on their own financial situation and doctor’s recommendations.

The mechanism of action of entrectinib is mainly to achieve the purpose of treatment by inhibiting the activity of ROS1, ALK and NTRK proteins in tumor cells. These proteins are abnormally activated in some cancer patients, promoting the growth and spread of tumor cells. Therefore, entrectinib can block the activity of these proteins, thereby inhibiting the growth and spread of cancer cells, and is expected to prolong patients' survival and improve their quality of life.

This medication is usually given as an oral tablet that patients can self-administer at home. In clinical trials, entrectinib has shown good tolerability and safety, but it may still have some side effects, such as nausea, vomiting, fatigue, diarrhea, etc. Therefore, during the use of entrectinib, doctors will closely monitor the patient's condition and physical condition and adjust the treatment plan as necessary.